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Background: Irritable bowel syndrome (IBS) is among the most common gastrointestinal disorders worldwide. In
selected patients with severe diarrhoea-predominant or mixed IBS subtypes sacral nerve stimulation (SNS) alleviates
IBS-specific symptoms and improves quality of life. The mode of action, however, remains unknown. The present
study aimed to evaluate the effect of SNS on small intestinal motility in IBS patients.
Methods: Twenty patients treated with SNS for severe diarrhoea-predominant or mixed IBS were included in a
randomised, controlled, crossover study. The neurostimulator was turned ON or OFF for the first one month and
then to the opposite setting for the next month. Gastrointestinal transit patterns were investigated with the Motility
Tracking System-1 (MTS-1) at the end of each the ON and OFF period. Primary endpoint was change in the velocity
of the magnetic pill within the small intestine. Statistical testing was performed with Wilcoxon’s rank sum test and
Fisher’s exact test.
Results: The median velocity of the magnetic pill through the small intestine in the fasting state was not significantly
different between periods with and without SNS (Group ON-OFF: median change 0 m/h (range −1.07, 0.63), Group
OFF-ON: median change 0.27 m/h (range −0.59, 1.12)) (p = 0.25). Neither, was the median velocity of the magnetic
pill through the small intestine in the postprandial state significantly different between periods with and without
SNS (Group ON-OFF: median change −0.13 m/h (range −0.46, 0.23), Group OFF-ON: median change 0.015 m/h
(range −0.48, 0.59)) (p = 0.14).
Conclusion: Even though SNS may reduce symptoms of diarrhoea-predominant and mixed IBS, it has no detectable
effect on small intestinal transit patterns.
Trial registration: Clinical.trials.gov, (NCT00919672).
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Irritable bowel syndrome (IBS) is among the most common
gastrointestinal disorders worldwide. Depending on the
criteria used, the reported prevalence ranges from 3-22%
of the general population [1-3]. Characteristics of IBS
include chronic recurrent abdominal pain associated with
a change in stool form and frequency as well as relief of
the abdominal pain by defecation. The aetiology of the
disorder is unknown, and there are no objective markers* Correspondence: janfas@rm.dk
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unless otherwise stated.available. Thus, diagnosis of IBS is based upon the Rome
III criteria [4]. Treatment of IBS is often unsatisfactory
and treatment modalities with acceptable long-term results
are needed.
Sacral nerves stimulation (SNS) is a minimally invasive
procedure introduced in 1995 by Matzel et al. [5]. An
electrode is placed through the sacral foramen and sub-
sequently connected with a neurostimulator to deliver
continuous stimulation to the nerve fibres. Initially, SNS
was used to treat idiopathic faecal incontinence. However,
indications have now spread to include faecal incontin-
ence secondary to anal sphincter lesions and severe cases
of intractable constipation. A pilot study has indicatedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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toms of IBS [6]. Recently, a randomised, controlled study
from our group has shown that permanent SNS for severe
diarrhoea-predominant or mixed IBS subtypes signifi-
cantly alleviates IBS-specific symptoms and improves
quality of life. Furthermore, SNS significantly reduces the
frequency of defecation, episodes of urgency, and time
spent on toilet [7].
The mechanism of action of SNS is unclear. Besides, a
direct effect on the efferent sacral nerves, SNS seems to
involve modulation of afferent signalling to the sacral
spinal cord resulting in neuromodulation at spinal and/
or supraspinal levels [8-10]. It is increasingly evident that
the effects of SNS extend beyond the segments of the
colorectum innervated by the sacral roots. Thus, changes
in contractility and transport have been demonstrated in
the right side of the colon during SNS for either faecal
incontinence or severe constipation [11,12].
Studies on small intestinal motility in IBS are not in full
agreement. Some have found specific abnormal motility
patterns correlating to the different IBS subtypes [13,14],
while others have found virtually no signs of dysmotility
[15,16].
The aim of this study was to evaluate the effect of SNS
on small intestinal motility in IBS patients of diarrhoea-
predominant and mixed subgroups. Our a priori hypothesis
was that SNS would prolong small intestinal transit.
Methods
Patients
Twenty patients (5 male, median age 31 years (range
19–48)) were included in a randomised, controlled, cross-
over design at our tertiary centre to assess small intestinal
motility after four weeks of each SNS (ON) and placebo
(OFF) (Figure 1). The patients included were identical to
the patients enrolled in the simultaneous study on the
treatment effect of SNS for IBS that has been described
in detail [7]. All patients had been diagnosed with IBS
according to the Rome III criteria and were characterisedFigure 1 Design of the randomised, controlled, crossover study.as having either diarrhoea-predominant (loose (mushy) or
watery stools > 25% and hard or lumpy stools < 25% of
bowel movements) (n = 11) or mixed IBS (hard or lumpy
stools > 25% and loose (mushy) or watery stools >25% of
bowel movements) (n = 9) [17]. Patients were bloc rando-
mised into two groups equal in size and allocation was
performed by a research nurse independent of the study.
Investigators were blinded to the setting of the stimulator
and patients were at no time informed about the setting.
Median time since implantation of the permanent neuro-
stimulator was 4 months (range 1–20 months).
None of the patients were taking any medication affect-
ing gastrointestinal motility. Before enrolment all patients
had to present with a normal sigmoidoscopy or colon-
oscopy including biopsies. Furthermore, tests for celiac
disease, thyroid disease, and lactose intolerance all had to
be normal. Age below 18 or above 70 years, pregnancy, and
severe psychological comorbidity were exclusion criteria.
Standard anal physiology tests including resting anal
pressure, squeeze pressure, rectal volume tolerability, anal
sensitivity, pudendal nerve motor latency, and endoanal
ultrasound were performed at baseline and results were
within the normal range previously published from our
unit [18].
Ethical approval (The National Committee on Health
Research Ethics, ID 20070218) was obtained at forehand
and all patients had signed written informed consent
before enrolment. The study was registered at clinical.
trails.gov (NCT00919672).
Motility Tracking System, MTS-1
This novel system tracks an orally ingested, cylindrical,
silicon-covered magnetic pill (dimensions 6x15 mm,
weight 0.9 g, and density 1.8 g cm-3) by a 4x4 matrix of
sensors positioned over the abdomen [19]. The system has
previously been validated and described in detail [20].
Prior to recordings, the sensor matrix was calibrated
by offsetting the earth’s and environmental magnetic fields.
With the magnet ingested, the position of the sensor plate
was registered with respect to anatomical reference points.
During recording, the magnetic induction measured by
each sensor was continuously transmitted to a computer
with a sampling rate of 10 Hz. With this information, the
magnets position and orientation was described according
to three directions (x, y, and z) and two inclination angles
(θ, φ). Changes in the magnets position coordinates reflect
propagation of the magnet, while a change in the magnets
orientation reflect rotation. The latter detects the specific
contraction frequency characteristic of the stomach, small
intestine and colon. Data processing and analysis were
continuously performed running custom-made software
(MTS_Record, Motilis, Lausanne, Switzerland) on a com-
puter showing the magnets real-time position and
orientation. Artefacts due to respiration and movements
Fassov et al. BMC Gastroenterology 2014, 14:111 Page 3 of 8
http://www.biomedcentral.com/1471-230X/14/111were detected using accelerometers placed on the neck
and upper abdomen.
After an overnight fast, the magnet was ingested at
10 AM and recordings proceeded until 16 PM. A stan-
dardised meal (a sandwich and a smoothie beverage, ~
1,500 kJ, 16% protein, 32% fat and 52% carbohydrate)
was served at 14 PM.
During investigations, patients were placed in a non-
magnetic bed with a head elevation (>45 degrees). They
were encouraged to keep talk and movement to a mini-
mum. Recordings were interrupted for small breaks
upon request.
Data analysis
Gastric emptying was defined as the time from ingestion
of the magnet until pyloric passage. Cessation of the
characteristic 3 gastric contractions per minute pattern,
appearance of the duodenal arch on the 2D picture, and
a consecutively beginning of the characteristic 8–10 small
intestinal contractions per minute pattern, were marks of
pyloric passage (Figure 2). Small intestinal transit was
defined as the time from pyloric passage until ileocecal
passage. Cessation of the 8–10 contractions per minute
pattern characteristic for the small intestine, a short burst
of a fast movement, and visualisation of the magnet in the
lower right quadrant of the abdomen on the 2D picture,
were marks of ileocecal passage.
Dedicated software (MTS_Tool, Motilis, Lausanne,
Switzerland) was used to compute the velocity (m/h) of
the magnetic pill for one hour following pyloric passage
and for one hour following ingestion of the standardised
meal. Based on previously performed analysis of velocity
histograms identifying a trimodal distribution, move-
ments were divided into fast (>15 cm per minute), slow
(between 1.5 and 15 cm per minute), and very slow
(<1.5 cm per minute) [21].
Statistics
Primary outcome parameter was the velocity of the mag-
netic pill within the small intestine.
The treatment effect (ON – OFF) was assessed by
computing the difference between period 1 and period 2
and comparing the distribution of these differences in
the two arms of the study. Likewise, the treatment
period interaction was assessed by computing the sum
in period 1 and period 2 and comparing the distribution
of these differences in the two arms of the study.
Data are provided as median (range) and counts (percent-
age). Statistical analysis was performed using Wilcoxon’s
rank sum test and Fisher’s exact test, with significance levels
set at 0.05.
Patients included in the present study were the same
as those included in a previous study on the effect of
SNS on IBS specific symptoms [7]. Sample size calculationwas based on expected change in symptoms and has been
presented previously. Therefore, no formal sample size
calculation was performed for changes in small intestinal
transit time.
Results
Patient demographics are shown in Table 1. MTS-1 in-
vestigations were well tolerated by all patients and no
procedure related adverse effects were observed.
Gastric emptying
All twenty patients were eligible for comparison of gastric
emptying. The characteristic 3 per minute contractions of
the stomach were present in all patients both in the ON
and OFF periods. We observed no statistical significant
difference in gastric emptying between periods with
and without neurostimulation (Group ON-OFF: median
change 3.5 min (range −304, 79), Group OFF-ON: median
change −33 min (range −128, 70)) (p > 0.09). No treatment
period interaction was observed (p > 0.05). Gastric empty-
ing times in the ON and OFF period are provided in
Table 2.
Small intestinal motility
In the fasting state, comparison of the velocity of the
magnet pill during the first hour following duodenal
passage was based on 19 patients. One patient had pro-
longed gastric emptying in the ON period (>360 minutes).
The characteristic 8–10 per minute small intestinal con-
traction pattern was present in all patients both during
ON and OFF periods. We found no statistically significant
difference between the velocity of the magnet pill during
periods with and without stimulation (Group ON-OFF:
median change 0 m/h (range −1.07, 0.63), Group OFF-ON:
median change 0.27 m/h (range −0.59, 1.12)) (p = 0.25).
The same was true for both subgroups (diarrhoea-predom-
inant and mixed IBS) (Table 3). No treatment period inter-
action was observed in any of the parameters (p > 0.05).
Median one hour velocities in the ON and OFF period
following duodenal passage are provided in Table 2.
In the postprandial state, comparison of the velocity of
the magnetic pill one hour following the standardised
meal was based on 17 patients. One patient had prolonged
gastric emptying time and in two patients the magnet
passed into the coecum, before the meal or before the end
of the first postprandial hour. We found no statistically
significant difference between the velocity of the magnet
pill during periods with and without stimulation (Group
ON-OFF: median change −0.13 m/h (range −0.46, 0.23),
Group OFF-ON: median change 0.015 m/h (range −0.48,
0.59)) (p = 0.14). This was also true for both subgroups
(diarrhoea-predominant and mixed IBS) (Table 3). No
treatment period interaction was observed in any of the
parameters (p > 0.05). Median one hour velocities in the
Figure 2 (See legend on next page.)
Fassov et al. BMC Gastroenterology 2014, 14:111 Page 4 of 8
http://www.biomedcentral.com/1471-230X/14/111
(See figure on previous page.)
Figure 2 Real time recording with MTS-1. A In the display to the left the postion x, y, and z and the orientation θ, and φ are visualised along
with the position of the sensor array over the body. To the right the concurrent recording of the magnetic pills movement through the duodenal arch
is displayed. B The duodenal passage is visualised as the magnetic pills change in position (x, y, and z) (arrow 1) in combination with disappearance of
the characteristic 3 contractions per minute patterns of the stomach (θ and φ) (arrow 2). The curve at the bottom detects artefacts from respiration
and movement.
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provided in Table 2.
Small intestinal passage occurred mainly during very
fast movements (>15 cm pr. min) accounting only for
a small proportion of time recorded. Comparing the
distribution of the differences in the two arms of the
study in the fasting state, there was no difference in
neither the proportion of time nor the distance covered
with fast, slow or very slow movements (Table 4).
Within the six hours protocol the magnet pill passed
into coecum in four (20%) patients during the ON period
and in five (25%) during the OFF period (p = 1.00).Discussion
In this randomised, controlled, crossover study among
patients with severe IBS we found no effect of SNS on
gastric emptying or small intestinal motility. This was
in spite of significantly reduced defecation frequencies,
urgency episodes, and time spent on the toilet [7]. Studies
on the effects of SNS on symptoms of IBS are very sparse
[6,7] and the physiological effects have not previously been
investigated. The lack of effect on small intestinal transit
in patients with IBS is, however, consistent with previously
published data on SNS in patients with faecal incontin-
ence [22,23]. In support, this study observed no treatment
period interaction in any of the parameters analysed.Table 1 Patients demographics
Study group N = 20
Age (years, median range) 31(19–48)
Men/women 5/15
Body Mass Index (kg/m2, median range) 25.5(18–37)
Diarrhoea-predominant/mixed IBS 11/9
Duration of IBS (patients)
1-5 years 5
6-10 years 9
> 11 years 6
Baseline symptom score in the GSRS-IBS
questionnaire (median range)
62(45–80)
Baseline quality of life score in the IBS-IS
questionnaire (median range)
136(82–180)
GSRS-IBS stands for Gastrointestinal Symptom Rating Scale – Irritable Bowel
Version (13 = no symptoms of IBS to 91 = severe IBS). IBS-IS stands for Irritable
Bowel Syndrome – Impact Scale (26 = no impact on daily life to 182 = severe
impact on daily life).In the present study, the small intestinal transit patterns
were almost identical with those previously reported
for healthy subjects [20]. Small intestinal dysmotility in
IBS has been a matter of discussion. In a recent study
using manometry there were few signs of small intestinal
dysmotility [15] and others have only found abnormal
small intestinal motility in IBS patients, who also had
delayed gastric emptying [16]. In contrast, studies using
scintigraphy or the hydrogen breath test have shown
that diarrhoea-predominant IBS patients have accelerated
small intestinal transit, while constipation-predominant
IBS patients have delayed small intestinal transit [13,14].
The mode of action of SNS is unclear. It is, however,
most likely that SNS, in addition to the direct effect on
efferent sacral nerve fibres, stimulates afferent fibres from
the distal colorectum to the spinal cord. Such afferent
stimulation may cause neuromodulation at spinal and/or
supraspinal levels. This is supported by evidence of altered
motility in the right side of the colon during SNS [11,12].
Furthermore, SNS alters cerebral evoked potentials and
reduces the overall corticoanal excitability during rectal
distension [9,24]. Thus, modulation through afferent nerve
fibres may be an important part of the mode of action of
SNS for IBS.
In the present study, SNS had a significant effect on
the frequency of defecation, episodes of urgency, and
time spent on toilet. Based on results from the same
patient group, we have previously reported that SNS alle-
viates IBS specific symptoms including pain, bloating,Table 2 Gastric emptying and one-hour velocities in the
small intestine in the ON and OFF period
ON period OFF period
Gastric emptying (minutes) (n = 20) 43 (5–360) 77 (4–142)
IBS-D (n = 11) 51 (9–159) 89 (34–142)
IBS-M (n = 9) 42 (5–360) 66 (4–121)
One-hour velocity following duodenal
passage (meters/hour) (n = 20)
1.29 (0.56-2.3) 1.19 (0.58-1.72)
IBS-D (n = 11) 1.29 (0.67-2.9) 1.19 (0.58-1.72)
IBS-M (n = 9) 1.1 (0.56-2.3) 1.12 (0.62-1.29)
One-hour velocity postprandial
(meters/hour) (n = 20)
0.48 (0.1-1.02) 0.42 (0.11-0.87)
IBS-D (n = 11) 0.49 (0.17-1.02) 0.36 (0.11-0.7)
IBS-M (n = 9) 0.48 (0.1-0.78) 0.46 (0.14-0.87)
IBS-D stand for diarrhoea-predominant IBS and IBS-M stand for mixed IBS.
Values are expressed as median and range.
Table 3 Inter-period change in the velocity of the magnet-capsule through the small intestine
One-hour following duodenal passage Change ON-OFF Change OFF-ON p
IBS-D and IBS-M (n = 19) 0 (−1.07, 0.63) 0.27 (−0.59, 1.12) 0.25
IBS-D (n = 11) 0.09 (−0.55, 0.45) 0.14 (−0.59, 1.12) 0.68
IBS-M (n = 8) −0.08 (−1.07, 0.63) 0.27 (0.22, 0.32) 0.32
One-hour following ingestion of meal Change ON-OFF Change OFF-ON p
IBS-D and IBS-M (n = 17) −0.13 (−0.46, 0.23) 0.01 (−0.48, 0.59) 0.14
IBS-D (n = 10) −0.04 (−0.17, 0.09) 0.16 (−0.09, 0.59) 0.30
IBS-M (n = 7) −0.13 (−0.46, 0.23) −0.31 (−0.48, −0.15) 0.26
IBS-D and IBS-M stand for diarrhoea-predominant and mixed irritable bowel syndrome. Values are expressed in meters pr. hour as median change (the difference
in the velocity of the magnet-capsule from ON to OFF or OFF to ON) and range.
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at least one year [7]. In patients with faecal incontinence,
the percutaneuos nerve evaluation test alters rectal sen-
sation to distension [9,24,25]. Most IBS patients have
visceral hypersensitivity [26,27] and abnormal engagement
of CNS regions associated with emotional arousal and en-
dogenous pain modulation has been documented during
rectal distension [28]. It is therefore possible, but remains
to be investigated, that SNS alters rectal sensitivity and
central processing of stimuli in IBS patients.
The strength of the present study is the randomised de-
sign. There are, however, important limitations and the
relatively small patient number may have caused a type II
error.
Even though patients were never informed of the actual
setting of their stimulator, fifteen out twenty patients were
able to tell correctly, whether the stimulator was turned
ON or OFF, wherefore, the study is not truly double-
blinded [7]. This may have caused a placebo effect. On
the other hand, all symptomatic effects of SNS were
maintained at least one year after implantation, which
speaks against the effect being solely placebo [7]. More-
over, setting the stimulation subsensory in patients with
constipation has been proved to eradicate the effect on
the colonic motility [29].
Time from implantation of the permanent stimulator
to inclusion varied considerably among patients in the
study. In a study from our unit on patients treated withTable 4 Small intestinal transit patterns during fast
Proportion of time with fast movements (percentage)
Distance covered during fast movements (cm)
Proportion of time with slow movements (percentage)
Distance covered during slow movements (cm)
Proportion of time with very slow movements (percentage)
Distance covered during very slow movements (cm)
Most of the distance covered by the magnetic pill during the first hour after pyloric
small proportion of the time. This was unaffected by SNS.
Fast movements (>15 cm/min), slow movements (between 1.5-15 cm/min), and ver
and range.SNS for faecal incontinence, symptoms reappeared within
a few hours after withdrawal of stimulation [30] and in
previous motility studies, the neurostimulators were turned
off only for one week before investigations [22,23]. Most
important, we observed no treatment period interaction in
the present study or in the study evaluating the effects of
SNS on IBS-specific symptoms and quality of life [7]. This
speaks against that time from implantation to inclusion into
the study is affecting small intestinal motility during SNS.
During fast a non-digestible object as the magnetic
pill will usually leave the stomach with an antral phase
III of the MMC [31,32]. This restricts the usefulness of
MTS-1 for estimating gastric emptying time. However,
in accordance with our results the scintigraphic study
by Damgaard et al. failed to detect any effect of SNS on
gastric emptying [23].
Practical and ethical reasons mandated that the record-
ings were limited to six hours as patients had to be almost
immobile. Therefore, we were only able to define the total
small intestinal transit time in a few patients. Such data
could have been obtained by scintigraphy. In contrast to
scintigraphy, the MTS-1 system allows continuous de-
scription of transit patterns and the MTS-1 has previously
allowed identification of abnormal small intestinal motility
in patients with systemic sclerosis, spinal cord injury and
carcinoid syndrome [33-35]. The study protocol for the
present study was based on experiences from those previ-
ous studies.ON-OFF group OFF-ON group p
−8 (−27, 53) 20.5 (−25, 55) 0.18
0 (−7, 5) 2 (−5, 6) 0.09
−2 (−53, 40) −16 (−60, 35) 0.44
−3 (−31, 10) 2.5 (−13, 22) 0.18
5 (−93, 12) 1 (−13, 7) 0.08
5 (−12, 32) −5 (−23, 16) 0.06
passage occurred during short bursts of fast movement only accounting for a
y slow movements (<1.5 cm/min). Values are expressed as median change
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limited to six hours, the assessment of the fasting small
intestinal motility was based on measurements during
the first hour after pyloric passage. This is too short to
allow us to draw any conclusions about the effects of
SNS on the migrating motor complex (MMC). Further-
more, the six hours protocol proved too short to allow
detailed description of colorectal motility even if patients
were studied on consecutive days.
Conclusion
SNS holds promise as an effective treatment modality
against severe diarrhoea-predominant or mixed IBS. Even
though, SNS reduces the frequency of defecation, episodes
of urgency, and time spent on toilet, this occurs without
major changes in small intestinal transit patterns. We
speculate that the effects of SNS in IBS may be caused
by modulation of afferent nerve fibres causing altered
colorectal sensory perception.
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